Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)

 

Effect of nintedanib on categorical changes in FVC in patients with progressive fibrosing ILDs: further analyses of the INBUILD trial

Maher TM et al.

 

Acceder

Continued treatment with nintedanib in patients with progressive fibrosing autoimmune disease‑related interstitial lung diseases: data from INBUILD‑ON

Matteson EL et al.

 

Acceder

Safety and tolerability of nintedanib in patients with autoimmune disease‑related interstitial lung diseases: pooled data from the SENSCIS and INBUILD trials

Smith V et al.
 

Acceder

 

SC-ES-08021